IRF8 as a Novel Marker to Differentiate Between CD30-Positive Large Cell Lymphomas. McQuaid DC, Katz SG, Xu ML. Am J Clin Pathol 2022;158:173-176.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

McQuaid DC, Katz SG, Xu ML. IRF8 as a Novel Marker to Differentiate Between CD30-Positive Large Cell Lymphomas. Am J Clin Pathol 2022;158:173-176.
PMID: 35460405